Journal article
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
M Hertzberg, MK Gandhi, J Trotman, B Butcher, J Taper, A Johnston, D Gill, SJ Ho, G Cull, K Fay, G Chong, A Grigg, ID Lewis, S Milliken, W Renwick, U Hahn, R Filshie, G Kannourakis, AM Watson, P Warburton Show all
Haematologica | FERRATA STORTI FOUNDATION | Published : 2017
Abstract
In the treatment of diffuse large B-cell lymphoma, a persistently positive [18F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a poor prognosis. In this prospective multi-center phase II study, we sought to establish whether treatment intensification with R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) chemotherapy followed by 90Y-ibritumomab tiuxetan–BEAM (BCNU, etoposide, cytarabine, and melphalan) for high-risk diffuse large B-cell lymphoma patients who are positive on interim PET scan after 4 cycles of R-CHOP-14 (rituximab, cyclophosphamide, doxorubicin, and prednisone) can improve 2-year progression-free survival from a historically unfavorable ra..
View full abstract